ArticleThe Lancet. Oncology2022
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply.
Thierry André et al.PubMed ↗Publisher ↗
No numbers read from the abstract.